Nothing on the Scale Yet? What the Trials Say About Slow Starters
In one semaglutide trial, 12% of people still hadn't lost 5% four weeks after reaching the full dose. Most of them got there anyway — here's the data.
You're three months in. Your appetite has genuinely changed. The scale has not moved. And the medication costs enough that "give it more time" is starting to sound like an excuse.
Here's what the trial data says about that position.
You're likely not on the dose the headline came from
The 14.9% average everyone quotes comes from STEP 1, at 2.4 mg. Nobody started there:
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.5 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17 onward | 2.4 mg |
Full dose arrives at week 16, and the trial then ran 52 more weeks there. At twelve weeks you're on 1.0 mg — under half the dose the headline was built on — with none of the maintenance phase behind you.
Key point
The early doses aren't meant to do much. They exist so your body meets the drug gradually. Judging it at 0.25 mg is judging something that wasn't trying to work yet.
"Below average" is still worth naming honestly
In STEP 4, participants ran a 20-week lead-in on semaglutide — the same escalation — and lost a mean of 10.6% before the randomised phase began.
So most people do see movement by three months. At zero, you're below average, and that's worth investigating rather than waiting out.
The part almost nobody quotes
A follow-up analysis of STEP 4 split people by whether they'd lost 5% at week 20 — four weeks after reaching full dose.
| At week 20 | Share | Average by week 68 |
|---|---|---|
| Lost 5% or more | 88.0% | -19.7% |
| Had not lost 5% | 12.0% | -6.4% |
That second row is the one to sit with. Those people had almost nothing to show well past full dose, and still finished down 6.4% on average.
The comparison that matters most: the same slow starters who were switched to placebo instead of continuing finished at -0.3%. The drug was working on them. It just hadn't surfaced on the scale.
About 57% of that group reached 5% or more by week 68. Early response strongly predicted success; early non-response barely predicted failure at all.
Two things worth ruling out first
Nausea snacking. Crackers, hard candy and cookies all settle a sour stomach, and it's easy to graze on them all day. Those calories rarely get counted, and they can quietly cancel out the smaller meals the medication is producing. Often the biggest available lever.
Side effects you've stopped mentioning. Constipation and ongoing nausea are treatable, and worth raising rather than managing alone — ondansetron, commonly prescribed for the nausea, lists constipation as a common side effect of its own.
What it adds up to
Flat at twelve weeks is below average and deserves a conversation. It is a long way from proof the medication won't work for you — and the trial data is clear that stopping is what turns a slow start into no result.
Important
General education, not medical advice. Whether to continue, adjust or stop any medication is a conversation with your own clinician, and persistent constipation or nausea should be reported to them rather than self-managed.
Sourcing note: the week-20 breakdown was presented as a conference abstract using STEP 4 data; the 10.6% lead-in figure and trial design come from the main JAMA paper.
Related: how much weight people lost on each medication and what else changes when the food noise stops.
This article is general education, not medical advice. Talk to your healthcare provider about your own treatment.